CVS Health Corporation
NYSE:CVSMedical - Healthcare Plans
-$0.59 today
- Market cap
- $104.08B
- Beta
- 0.62
- P/E (TTM)
- 42.8
- EPS (TTM)
- $2.30
- Dividend yield
- 2.70%
Volume 17.19M
Average 8.19M
CVS Total Current Liabilities
All obligations due within one year.
CVS Health CorporationNYSE: CVS
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities falls 7.6% from a year ago
Total current liabilities stood at $87.04B at the end of Q2 FY2026, down 7.6% from a year earlier and up 0.7% from the prior quarter. Over 3 fiscal years it compounded at +8.5% a year.
Context
- Total current liabilities amounted to 34.3% of total assets at the end of Q2 FY2026, down 2.1 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -7.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 88.69B USD
- Year-over-year change
- +4.8%
- 4-year CAGR
- +6.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 88.69B | +4.8% |
| FY2024 | 2024-12-31 | 84.61B | +6.8% |
| FY2023 | 2023-12-31 | 79.19B | +14.1% |
| FY2022 | 2022-12-31 | 69.42B | +2.4% |
| FY2021 | 2021-12-31 | 67.81B | — |
Total Current Liabilities vs competitors
How CVS compares with its peers on the latest reported figures
- CVS's Jun 2026 total current liabilities of $87.04B is the 2nd highest of the 9 companies compared; the peer median is $32.41B.
- Its year-over-year change of -7.6% is the lowest of 9, against a peer median of +27.2%.
- Total current liabilities amounts to 34.3% of total assets for CVS, versus a peer median of 44.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $115.84B | +0.3% | +8.8% | 37.0% | |
| Jun 2026 | $87.04B | -7.6% | +8.5% | 34.3% | |
| Sep 2026 | $56.03B | -0.7% | +11.0% | 35.5% | |
| Sep 2026 | $46.66B | +158.1% | +2.3% | 36.5% | |
| Jun 2026 | $40.76B | +10.8% | -9.0% | 49.1% | |
| Sep 2026 | $24.05B | +132.3% | -3.9% | 42.0% | |
| Jun 2026 | $8.69B | +78.6% | +17.9% | 77.4% | |
| Sep 2026 | $7.39B | -1.2% | +2.5% | 47.2% | |
| Mar 2026 | $655.97M | +43.5% | +27.5% | 52.0% | |
| Peer median (excluding CVS) | $32.41B | +27.2% | +5.6% | 44.6% | |
Competitors are the stored peer set for CVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9.41B | 12.95B | 8.2B | 8.59B | 8.51B |
| Short-term Investments | 3.12B | 2.78B | 3.26B | 2.41B | 2.15B |
| Net Receivables | 24.43B | 27.28B | 35.23B | 36.47B | 39.78B |
| Inventory | 17.76B | 19.09B | 18.03B | 18.11B | 19.25B |
| Other Current Assets | 5.29B | 3.54B | 3.15B | 3.08B | 5.03B |
| Total Current Assets | 60.01B | 65.63B | 67.86B | 68.65B | 74.71B |
| Property, Plant & Equipment (Net) | 32.02B | 30.75B | 30.44B | 28.94B | 28.06B |
| Goodwill | 79.12B | 78.15B | 91.27B | 91.27B | 85.48B |
| Intangible Assets | 29.03B | 24.8B | 29.23B | 27.32B | 25.51B |
| Long-term Investments | 23.03B | 21.1B | 23.02B | 28.93B | 32.87B |
| Tax Assets | 0 | 0 | 0 | 0 | 7.53B |
| Other Non-current Assets | 9.8B | 7.85B | 7.91B | 8.1B | 6.91B |
| Total Non-current Assets | 172.99B | 162.64B | 181.87B | 184.57B | 186.35B |
| Total Assets | 233B | 228.28B | 249.73B | 253.22B | 261.06B |
| Account Payables | 12.54B | 14.84B | 14.9B | 15.89B | 59.38B |
| Short-term Debt | 4.21B | 1.78B | 2.97B | 5.74B | 5.81B |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 62M |
| Other Current Liabilities | 5.6B | 2.82B | 2.47B | 1.18B | 23.42B |
| Total Current Liabilities | 67.81B | 69.42B | 79.19B | 84.61B | 88.69B |
| Long-term Debt | 51.97B | 50.48B | 58.64B | 60.53B | 72.88B |
| Deferred Tax Liabilities | 6.27B | 4.02B | 4.31B | 3.81B | 11.36B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 13.39B | 15.79B | 14.92B | 13.64B | (2.16B) |
| Total Non-current Liabilities | 89.81B | 87.09B | 93.9B | 92.88B | 96.99B |
| Total Liabilities | 157.62B | 156.51B | 173.09B | 177.49B | 185.68B |
| Common Stock | 47.38B | 48.19B | 48.99B | 18M | 18M |
| Retained Earnings | 54.91B | 56.4B | 61.6B | 62.84B | 61.2B |
| Accumulated OCI | 965M | (1.26B) | (297M) | (120M) | 406M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 306M | 300M | 175M | 170M | 168M |
| Total Equity | 75.38B | 71.77B | 76.64B | 75.73B | 75.38B |
| Total Debt | 76B | 70.73B | 79.39B | 82.92B | 93.59B |
| Net Debt | 66.59B | 57.79B | 71.19B | 74.33B | 85.08B |
CVS Health Corporation
NYSE:CVS
Intrinsic Alpha fair value
Locked
Current Price
$81.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.